The Official MicroCap News Source
Watchlist News
Please Login or Register to view News Stories

Healthcare & Insurance

Novartis receives European Commission approval for self-administration of Xolair® across all indications

The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe[1]  Xolair® (omalizumab) prefilled syringe (PFS) is the first and only biologic to receive European Commission (EC) approval for self-administration

Thursday, December 13, 2018

Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

RADNOR, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of $3.75 per share. The total public offering

Thursday, December 13, 2018

Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment

- Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - - Presentation Today at the 57th Annual Meeting of the American College of Neuropsychopharmacology - DEVON, Pa., Dec. 12, 2018 (GLOBE

Wednesday, December 12, 2018

Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the closing of its

Wednesday, December 12, 2018

Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018

EXTON, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined

Wednesday, December 12, 2018

AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study; Termination of Biogen Collaboration

- Results from XLRS study support general safety and tolerability of AGTC’s gene delivery platform but did not demonstrate signs of clinical activity at interim six-month time point -- AGTC to regain rights to five clinical and preclinical development programs; Biogen terminates collaboration

Wednesday, December 12, 2018

VBI Vaccines Announces Proposed Public Offering of Common Shares

CAMBRIDGE, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has commenced an underwritten public offering of its common

Wednesday, December 12, 2018

Veterinarians are in control: Medical insurance for pets can avoid pitfalls of human health insurance  

SEATTLE, Dec. 12, 2018 (GLOBE NEWSWIRE) -- While human health insurance models – each with its own set of problems – are debated all over the world, medical insurance for pets is currently avoiding such criticism and can continue to do so with input from veterinarians. Human medical

Wednesday, December 12, 2018

Advanzeon Solutions, Inc.’s Wholly-Owned Subsidiary Pharmacy Value Management Solutions, Inc. Announces Medical Director and Members of Its Medical

TAMPA, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Advanzeon Solutions, Inc.’s (OTCBB:CHCR) ("Advanzeon") wholly-owned subsidiary, Pharmacy Value Management Solutions, Inc. ("PVMS") (collectively, the "Company"), announced today that its Medical Director and many members of its Medical Advisory

Wednesday, December 12, 2018

Easton Pharmaceuticals Provides Company Update Including Hotel Acquisition in Toronto, BAYER Agreement and Casino Resort in Greece

TORONTO, ON, Dec. 12, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Easton Pharmaceuticals Inc. (OTC: EAPH) Provides Company update including Hotel Acquisition in Toronto, BAYER Distribution Agreement for Mexico, as well as the Casino and Hotel Resort acquisition in Greece. As previously

Wednesday, December 12, 2018

Aptose Presents Highlights From CG-806 KOL Event

Dr. Brian Druker Reviews AML and B-cell Cancer Treatment Landscape and Provides Update on Novel Multi-Cluster Kinase Inhibitor CG-806SAN DIEGO and TORONTO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a Key Opinion Leader (KOL)

Wednesday, December 12, 2018

Ceapro Inc. Presents PGX Technology at the Society of Cosmetic Chemists’ 72nd Annual Scientific Meeting and Technology Showcase

EDMONTON, Alberta, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Paul Moquin,

Wednesday, December 12, 2018

Phoenix Life Sciences International Is Now Accepting Bids for Hemp CBD Producers and Manufacturers

DENVER, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it is now accepting bids from U.S. licensed producers of industrial hemp to supply various products

Wednesday, December 12, 2018

iAnthus and MPX Announce Receipt of Interim Court Order

NEW YORK and TORONTO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. (“iAnthus” or “the Company”), (CSE: IAN, OTCQB: ITHUF) and MPX Bioceutical Corporation (“MPX”) (CSE: MPX; OTC:MPXEF) announced today that on December 10, 2018, MPX was granted an interim order from

Wednesday, December 12, 2018

CV Sciences, Inc. Receives Nutritional Outlook’s 2018 Best of the Industry Award

Company’s industry-dominating hemp extract brand, PlusCBD Oil™ wins Best Retail/Brand Product category LAS VEGAS, Dec. 12, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “CV Sciences”, “our” or “we”), preeminent supplier and manufacturer of

Wednesday, December 12, 2018

Terra Tech Subsidiary Edible Garden to Participate in The New York Produce Show and Conference December 12th

IRVINE, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Terra Tech Corp. (TRTC) ("Terra Tech") or (the "Company"), a vertically integrated cannabis-focused agriculture company, today announced that its wholly-owned subsidiary, Edible Garden, will participate in the New York Produce Show and Conference,

Wednesday, December 12, 2018

Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research

ROCHESTER, N.Y., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative

Wednesday, December 12, 2018

Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta™ for M207

FREMONT, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proposed brand name

Wednesday, December 12, 2018

Kane Biotech Launches Four New bluestem™ Products

WINNIPEG, Manitoba, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced it will be launching 4 new products under its bluestem™ brand in Canada and the United States in the first quarter of 2019. The four

Wednesday, December 12, 2018

XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease

Bermekimab Therapy Rapidly and Significantly Reduces DiseaseAUSTIN, Texas, Dec. 12, 2018 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) has

Wednesday, December 12, 2018

loading

© 2018 Stock News Now